PubRank

Sitagliptin Cardiovascular Outcomes Study (MK-0431-082) (TECOS)

Clinical Trial ID NCT00790205

PubWeight™ 45.50‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00790205

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015 9.70
2 Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2013 2.66
3 Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med 2012 2.13
4 Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab 2012 1.55
5 Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J Diabetes Investig 2013 1.55
6 A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf 2012 1.17
7 Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol 2013 1.17
8 Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol 2016 1.13
9 Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol 2012 1.05
10 Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2014 1.05
11 The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups. Adv Ther 2013 0.98
12 Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Metab Syndr Obes 2010 0.98
13 DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res 2015 0.93
14 Incretin agents in type 2 diabetes. Can Fam Physician 2010 0.92
15 Do GLP-1-based therapies increase cancer risk? Diabetes Care 2013 0.92
16 Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol 2014 0.87
17 Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clin Proc 2011 0.87
18 Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Obes Metab 2015 0.87
19 Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus. J Diabetes Investig 2015 0.87
20 Incretin-based therapies: focus on effects beyond glycemic control alone. Diabetes Ther 2013 0.84
21 The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol 2013 0.83
22 Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials. Diabetes Ther 2016 0.82
23 Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents. Nephrol Dial Transplant 2015 0.82
24 Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin. Drug Des Devel Ther 2013 0.81
25 Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke. J Cereb Blood Flow Metab 2015 0.81
26 Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol 2014 0.80
27 Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials. J Diabetes Res 2015 0.79
28 Play of Chance Versus Concerns Regarding Dipeptidyl Peptidase-4 Inhibitors: Heart Failure and Diabetes. Clin Diabetes 2014 0.79
29 Current perspectives on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol 2016 0.79
30 Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis? Biomed Res Int 2015 0.78
31 Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data? Diabetes Ther 2016 0.77
32 Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety. Adv Ther 2015 0.77
33 Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment. Diabetes Metab Syndr Obes 2013 0.77
34 The effects of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risks in type 2 diabetes mellitus. J Diabetes Res 2013 0.77
35 Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care 2016 0.76
36 Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure. Int J Mol Sci 2015 0.76
37 Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications. Clin Pharmacol Ther 2015 0.75
38 Cardiovascular effects of anti-diabetes drugs. Expert Opin Drug Saf 2016 0.75
39 Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements. Diabetes Metab Syndr Obes 2015 0.75
40 Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial. Herz 2016 0.75
Next 100